Gene-Circuit Cell Therapy Market Report 2026

The gene-circuit cell therapy market size has grown exponentially in recent years. It will grow from $1.38 billion in 2025 to $1.67 billion in 2026 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to advances in cell engineering technologies, success of car-t cell therapies, expansion of gene editing platforms, growing clinical experience with cell therapies, increased biotechnology investments.

The gene-circuit cell therapy market size is expected to see exponential growth in the next few years. It will grow to $3.56 billion in 2030 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to increasing commercialization of gene-circuit cell therapies, rising demand for controllable immunotherapies, expansion of oncology-focused pipelines, growing adoption of allogeneic platforms, advancements in scalable cell manufacturing. Major trends in the forecast period include increasing adoption of synthetic gene circuits in cell therapy, rising development of logic-controlled immune cells, growing use of off-the-shelf allogeneic therapies, expansion of dynamic cellular response systems, enhanced focus on treatment safety and control.

The increasing adoption of personalized medicine is expected to propel the growth of the gene-circuit cell therapy market in the coming years. Personalized medicine is a medical approach that customizes treatment and prevention strategies based on an individual’s unique genetic profile, lifestyle, and environment. The rising adoption of personalized medicine is largely driven by advances in genomics, which allow for precise identification of genetic variations and tailored treatments for patients. Gene-circuit cell therapy complements personalized medicine by providing targeted and programmable treatment options, making it particularly suitable for complex and chronic conditions. It improves therapeutic accuracy by customizing interventions to meet individual patient needs, enhancing treatment efficacy and overall health outcomes. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Consequently, the growing adoption of personalized medicine is driving the expansion of the gene-circuit cell therapy market.

Major companies operating in the gene-circuit cell therapy market are concentrating on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, to improve treatment precision, enhance therapeutic outcomes, and target previously untreatable genetic disorders. CRISPR-based gene editing systems are innovative technologies that allow precise modifications to the genome, enabling the correction of genetic defects or the introduction of therapeutic genes into cells. For example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, collaborated with CRISPR Therapeutics Inc., a US-based biotechnology research company, and received conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). It is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which reduces or eliminates disease symptoms and provides a potential functional cure for these conditions.

In May 2025, AstraZeneca PLC, a UK-based pharmaceutical company, acquired EsoBiotec for an undisclosed sum. Through this acquisition, AstraZeneca intends to accelerate and expand its in vivo cell therapy capabilities, with a focus on making transformative treatments for cancer and immune-mediated diseases more accessible and effective. EsoBiotec BV is a Belgium-based biotechnology company that specializes in developing gene-circuit cell therapies.

Major companies operating in the gene-circuit cell therapy market are Tmunity Therapeutics Inc., Ginkgo Bioworks Holdings Inc., Arcellx Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Intellia Therapeutics Inc., Orchard Therapeutics plc, Fate Therapeutics Inc., Rubius Therapeutics Inc., BlueRock Therapeutics LP (a subsidiary of Bayer AG), Precigen Inc., SparingVision, Alaunos Therapeutics Inc., Cartesian Therapeutics Inc., Lyell Immunopharma Inc., Synlogic Inc., Senti Biosciences Inc., Autolus Therapeutics plc, Cellectis S.A., Sotio Biotech.

North America was the largest region in the gene-circuit cell therapy market in 2025. The regions covered in the gene-circuit cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene-circuit cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the gene-circuit cell therapy market by increasing costs of imported cell processing equipment, gene editing tools, bioreactors, cryopreservation systems, and analytical instruments. Biotechnology companies and hospitals in North America and Europe are most affected due to reliance on imported manufacturing infrastructure, while Asia-Pacific faces higher costs for therapy scale-up. These tariffs are increasing production expenses and impacting pricing strategies. However, they are also encouraging local cell manufacturing facilities, regional supply chain development, and innovation in cost-optimized cell therapy production technologies.

The gene-circuit cell therapy market research report is one of a series of new reports that provides gene-circuit cell therapy market statistics, including gene-circuit cell therapy industry global market size, regional shares, competitors with a gene-circuit cell therapy market share, detailed gene-circuit cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene-circuit cell therapy industry. This gene-circuit cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene-circuit cell therapy is a sophisticated type of cell therapy in which engineered cells are designed with synthetic gene circuits that enable them to detect, process, and respond to specific biological signals within the body. It facilitates controlled, targeted, and dynamic therapeutic actions such as delivering drugs, regulating immune activity, or correcting abnormal cellular functions, improving precision and safety compared to traditional cell therapies.

The main product types of gene-circuit cell therapy are autologous and allogeneic. Autologous therapy involves a treatment method in which a patient’s own cells are collected, genetically modified with synthetic gene circuits to detect and respond to specific biological signals, and then reinfused into the same patient. It employs advanced technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), zinc finger nuclease (ZFN), among others, and is applied in the treatment of oncology, genetic disorders, infectious diseases, and more. The primary end users include hospitals and clinics, research institutes, biotechnology and pharmaceutical companies, and others.

The gene-circuit cell therapy consists of revenues earned by entities by providing services such as cell engineering and programming, patient monitoring, therapeutic response customization, and clinical trial support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene-circuit cell therapy also includes sales of engineered therapeutic cells, synthetic gene circuit constructs, cell therapy kits, reagents, and supporting delivery systems or devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.